For the first time in history, high blood pressure is more common in lower-income countries

For the first time in history, high blood pressure is more common in lower-income countries

American Heart Association Rapid Access Journal Report

American Heart Association

DALLAS, August 8, 2016 — For the first time in history, people living in low- and middle-income countries have a higher prevalence of hypertension – or high blood pressure – than people living in high-income countries, according to new research in the American Heart Association’s journal Circulation.

A 2010 data analysis involving more than 968,000 participants from 90 countries found that more than 30 percent of adults worldwide live with high blood pressure, and 75 percent of those adults live in low- and middle-income countries.

Hypertension is a major risk factor for heart disease and stroke as well as the leading preventable cause of premature death and disability worldwide. Past reports have shown that the prevalence of hypertension is increasing in low- and middle-income countries while it is steady or decreasing in high-income countries, but recent estimates of this global disparity are unknown.

In this study, researchers used sex- and age-specific high blood pressure prevalence from 131 past reports to calculate the regional and global estimates of hypertensive adults.

Researchers found:

In 2010, 31.1 percent (1.39 billion) of the adult population worldwide had high blood pressure, 28.5 percent (349 million) of adults in high-income countries and 31.5 percent (1.04 billion) of adults in low- and middle-income countries.

High blood pressure prevalence decreased by 2.6 percent in high-income countries while increasing 7.7 percent in low- and middle-income countries between 2000 and 2010.

In high-income countries, significantly improvements were noted from 2000 to 2010: awareness increased from 58.2 percent to 67.0 percent, treatment rates improved from 44.5 percent to 55.6 percent and control increased from 17.9 percent to 28.4 percent.

In low- and middle-income countries, awareness slightly improved from 32.3 percent to 37.9 percent and treatment increased from 24.9 percent to 29.0 percent from 2000 to 2010, but control worsened from 8.4 percent to 7.7 percent.

There are many reasons for these global disparities.

“Aging populations and urbanization, which is often accompanied by unhealthy lifestyle factors, such as high sodium, fat and calorie diets and lack of physical activity, may play an important role in the epidemic of hypertension in low- and middle-income countries,” said Jiang He, M.D., Ph.D., senior study author and researcher at Tulane University School of Public Health and Tropical Medicine in New Orleans, Louisiana.

“Healthcare systems in many low- and middle-income countries are overburdened and do not have the resources to effectively treat and control hypertension,” He said. “In addition, because hypertension is symptomless and many people in low- and middle-income countries do not have access to screenings or regular preventative medical care, it is often underdiagnosed.”

Researchers noted that most of the world’s population is represented in the study, but more than half of the countries worldwide didn’t have data on hypertension prevalence, so there may be some inaccuracies in their regional and global estimates of adults living with high blood pressure.

“Hypertension needs to be a public health priority in low- and middle-income countries to prevent future cardiovascular and kidney disease, and associated costs to society,” said Katherine T. Mills, Ph.D., lead author and researcher at Tulane University. “Collaboration is needed from national and international stakeholders to develop innovative and cost-effective programs to prevent and control this condition.”

Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association’s policy or position. The association makes no representation or guarantee as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at http://www.heart.org/corporatefunding.